SQLite Web: event_store.db

Could not fetch row with primary-key sig_4b7d549501f6.

Could not fetch row with primary-key sig_15027586642d.

Update row sig_fb59fcc2302c in signals

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001123343-26-000002.txt","as_of":"2026-04-17T02:13:18.114675+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001123343-26-000002.txt","company":"Travere Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001123343-26-000002.txt","article_chars":2177,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_78f84d4f261a6f21","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001123343-26-000002.txt","content_type":"text/plain","enriched_at":"2026-04-17T06:22:27.851674+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001123343-26-000002.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001123343-26-000002.txt","source_event_id":"evt_5ae842166ea7","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"a57248f5ef7e8e02","kind":"sec_filing","published_at":"20260416","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2026-04-14","2026-04-16","2026-05-18","2025-11-11","2013-02-20","2008-06-25"],"entities":[{"asset_class":"equity","name":"Travere Therapeutics, Inc.","relevance":"high","symbol":"TVTX","type":"issuer"},{"asset_class":"person","name":"Gary A. Lyons","relevance":"high","symbol":"","type":"reporting_owner"},{"asset_class":"equity","name":"Common Stock","relevance":"high","symbol":"","type":"security"},{"asset_class":"equity_derivative","name":"Stock option (right to buy)","relevance":"medium","symbol":"","type":"security"}],"event_type":"listing","information_gaps":["The provided text does not clearly state whether the reported transaction is an outright sale after option exercise versus a sale of option shares; it only states \u201csale of shares underlying a stock option.\u201d","The provided text includes price-related fields (e.g., 16.33 and 41.07) but does not explicitly label them as sale price vs. exercise price in a way that can be unambiguously mapped.","No prior known state is included in the signal beyond the generic \u201cdelta\u201d framing, so the exact change vs prior state cannot be determined from the provided text alone."],"key_facts":["SEC filing: Form 4 (CONFORMED SUBMISSION TYPE: 4).","Issuer: Travere Therapeutics, Inc. (TVTX).","Reporting person: Gary A. Lyons (CENTRAL INDEX KEY: 0001123343).","Conformed period of report: 2026-04-14; filed as of date: 2026-04-16.","The transaction described as a sale of shares underlying a stock option granted to the reporting person with an expiration date of 2026-05-18.","The stock option is stated as fully vested and exercisable.","The sale was made pursuant to a written plan adopted on 2025-11-11 meeting Rule 10b5-1(c) requirements.","The filing shows 8,000 shares in the transaction lines (quantity appears as 8000).","The filing includes a signature: /s/ Elizabeth E. Reed, Attorney-in-Fact dated 2026-04-16."],"numeric_claims":[{"label":"shares_quantity","value":"8000"},{"label":"option_expiration_date","value":"2026-05-18"},{"label":"10b5-1_plan_adoption_date","value":"2025-11-11"},{"label":"conformed_period_of_report","value":"2026-04-14"},{"label":"filed_as_of_date","value":"2026-04-16"}],"primary_claim":"Form 4 filed 2026-04-16 by Travere Therapeutics, Inc. reports a sale of 8,000 shares underlying a fully vested stock option (expiring 2026-05-18) by Gary A. Lyons pursuant to a Rule 10b5-1(c) plan adopted 2025-11-11.","relevance_score":0.55,"sentiment":"neutral","source_quality":"medium","summary":"Travere Therapeutics, Inc. (TVTX) filed a Form 4 on 2026-04-16 reporting a transaction by reporting person Gary A. Lyons. The filing indicates the sale of shares underlying a fully vested, exercisable stock option expiring May 18, 2026, pursuant to a Rule 10b5-1(c) plan adopted on November 11, 2025.","topics":["SEC Form 4","insider transaction","Rule 10b5-1(c) plan","stock option exercise/sale","common stock"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 Travere Therapeutics, Inc. \u00b7 Filed 20260416","ticker":"TVTX","tickers":["TVTX"],"title":"TVTX filed 4","url":"https://www.sec.gov/Archives/edgar/data/1438533/0001123343-26-000002.txt"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel